Ken Griffin Bio Path Holdings Inc Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$0.36 - $0.75 $8,710 - $18,146
24,195 New
24,195 $11,000
Q1 2023

May 15, 2023
BUY
$1.39 - $2.26 $21,785 - $35,420
15,673 Added 79.24%
35,451 $49,000
Q4 2022

Feb 14, 2023
BUY
$1.32 - $69.2 $11,732 - $615,049
8,888 Added 81.62%
19,778 $29,000
Q3 2022

Nov 14, 2022
BUY
$3.18 - $66.0 $34,630 - $718,740
10,890 New
10,890 $35,000

About BIO-PATH HOLDINGS INC

BPTH Quotes by TradingView
  • Ticker BPTH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 7,160,160
  • Market Cap $6.37M
  • Description
  • Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the...
More about BPTH
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email